Management of residual risk after statin therapy

2015/12/17 by Christina Reith, Jane Armitage · 25 citations
Medicine · Economics, Econometrics and Finance · #Lipoproteins and Cardiovascular Health #Health Systems, Economic Evaluations, Quality of Life #Pharmaceutical Economics and Policy

paper · doi:10.1016/j.atherosclerosis.2015.12.018

Citations

• Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

Cited by

• Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages. [europepmc]
• Atherosclerosis Is an Epigenetic Disease. [europepmc]
• Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. [europepmc]
• Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. [europepmc]
• Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. [europepmc]
• Red Wine Grape Pomace Attenuates Atherosclerosis and Myocardial Damage and Increases Survival in Association with Improved Plasma Antioxidant Activity in a Murine Model of Lethal Ischemic Heart Disease. [europepmc]
• Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention. [europepmc]
• Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy. [europepmc]
• Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. [europepmc]
• Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment. [europepmc]
• Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. [europepmc]
• Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. [europepmc]
• Increased Circulating Malondialdehyde-Modified Low-Density Lipoprotein Level Is Associated with High-Risk Plaque in Coronary Computed Tomography Angiography in Patients Receiving Statin Therapy. [europepmc]
• Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis. [europepmc]
• The Role of Colchicine in Atherosclerosis: From Bench to Bedside. [europepmc]
• Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. [europepmc]
• Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study. [europepmc]
• Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study. [europepmc]
• Additive effect between homocysteine and low-density-lipoprotein cholesterol upon incidence of novel carotid plaque formation: data from a Chinese community-based cohort. [europepmc]
• Association of statin use and increase in lipoprotein(a): a real-world database research. [europepmc]
• GM-CSF receptor/SYK/JNK/FOXO1/CD11c signaling promotes atherosclerosis. [europepmc]
• Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes. [europepmc]
• Sugar and Dyslipidemia: A Double-Hit, Perfect Storm. [europepmc]
• The chylomicron saga: time to focus on postprandial metabolism. [europepmc]
• Deciphering single-cell landscape unravels cell-type-specific functional roles of RNA m 6 A modification in atherosclerosis. [europepmc]